Key result
Patients with fatty liver disease require cardiovascular risk assessment and consideration of statin therapy, as emerging drugs may have both adverse and beneficial effects on cardiovascular risk.
Why the study?
Fatty liver disease is increasingly common worldwide and is associated with an increased risk of cardiovascular disease.
Patients with metabolic-associated fatty liver disease require comprehensive cardiovascular risk assessment and consideration of statin therapy due to elevated CVD risk.
Answers are grounded in this paper and cite their sources.
Fatty liver warrants CVD risk assessment with statin consideration; leaves open net cardiovascular effects of emerging therapies.
PURPOSE OF REVIEW: Fatty liver disease is increasingly common worldwide and is associated with an increased risk of cardiovascular disease (CVD). RECENT FINDINGS: This review describes the cardiovascular outcomes, clinical assessment and management as well as the impact of emerging drug treatment on CVD risk. SUMMARY: Patients with fatty liver require CVD risk assessment including consideration of statin therapy. Emerging therapeutic drugs for fatty liver may have both adverse and beneficial effects on CVD risk.
No takes yet. Share an insight, caveat, or question.
Leon A. Adams (2023) conducted a review in Metabolic-associated fatty liver disease. Emerging therapeutic drugs and statin therapy was evaluated. Patients with fatty liver disease require cardiovascular risk assessment and consideration of statin therapy, as emerging drugs may have both adverse and beneficial effects on cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: